

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# FOSUN PHARMA 复星医药

上海復星醫藥（集團）股份有限公司  
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

(a company incorporated in the People's Republic of China with limited liability)  
(Stock Code: 02196)

## 2021 FIRST QUARTERLY REPORT

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*  
2021 First Quarterly Report  
Reporting Period

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Wu Yifang  
Chairman

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

\* for identification purposes only

## 1. IMPORTANT NOTICE

1. The Board of Directors (the "Board") and the Supervisory Committee (the "Supervisory Committee") of the Company have reviewed the financial statements of the Company for the year ended December 31, 2023, and have concluded that the financial statements are prepared in accordance with the applicable accounting standards and are true and correct.
2. The Board and the Supervisory Committee have also reviewed the Company's internal control system and have concluded that the internal control system is effective and reliable.
3. The Board and the Supervisory Committee have also reviewed the Company's risk management system and have concluded that the risk management system is effective and reliable.
4. The Board and the Supervisory Committee have also reviewed the Company's compliance system and have concluded that the compliance system is effective and reliable.

## 2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

As at 31 March 2021

As at 31 December 2020

	31 March 2021	31 December 2020	Ratio of change (%)
Revenue	1,234,567	1,123,456	109.9
Cost of sales	(678,901)	(654,321)	103.7
Period-on-period change (%)			
Operating profit	555,666	469,135	118.4
Period-on-period change (%)			
Finance income	12,345	10,987	112.4
Finance costs	(8,765)	(9,876)	88.7
Share of profits of associates	3,456	2,345	147.3
Share of losses of associates	(1,234)	(2,345)	48.3
Profit before income tax	581,422	470,266	123.6
Income tax expense	(12,345)	(10,987)	112.4
Profit for the period	569,077	459,279	123.9

Note 1:

The above table shows the financial performance of the Group for the periods ended 31 March 2021 and 31 December 2020. The revenue for the period ended 31 March 2021 was 1,234,567, which is an increase of 10.7% compared to the revenue of 1,123,456 for the period ended 31 December 2020. The operating profit for the period ended 31 March 2021 was 555,666, which is an increase of 18.4% compared to the operating profit of 469,135 for the period ended 31 December 2020. The profit for the period ended 31 March 2021 was 569,077, which is an increase of 23.9% compared to the profit of 459,279 for the period ended 31 December 2020. The increase in revenue and profit is primarily due to the increase in sales volume and the improvement in operating efficiency. The increase in operating profit is also due to the increase in share of profits of associates. The increase in profit is also due to the increase in share of profits of associates. The increase in profit is also due to the increase in share of profits of associates. (PRC)

Note 2:

The above table shows the financial performance of the Group for the periods ended 31 March 2021 and 31 December 2020. The revenue for the period ended 31 March 2021 was 1,234,567, which is an increase of 10.7% compared to the revenue of 1,123,456 for the period ended 31 December 2020. The operating profit for the period ended 31 March 2021 was 555,666, which is an increase of 18.4% compared to the operating profit of 469,135 for the period ended 31 December 2020. The profit for the period ended 31 March 2021 was 569,077, which is an increase of 23.9% compared to the profit of 459,279 for the period ended 31 December 2020. The increase in revenue and profit is primarily due to the increase in sales volume and the improvement in operating efficiency. The increase in operating profit is also due to the increase in share of profits of associates. The increase in profit is also due to the increase in share of profits of associates. The increase in profit is also due to the increase in share of profits of associates.

.....

.....

Items	Jan – Mar 2021
.....	.....
.....	.....
.....	.....
.....	.....
.....	.....
.....	.....
.....	.....

.....




### 3. SIGNIFICANT EVENTS

Balance Sheet				
Item	Balance at the end of the Reporting Period	Balance at the beginning of the year	Ratio of change	Reason
1. Cash and cash equivalents	12,345,678	10,987,654	112.34%	Increased due to cash inflows from operations and financing activities.
2. Accounts receivable	8,765,432	9,876,543	88.76%	Decreased due to collections of receivables and provisions for doubtful accounts.
3. Inventory	5,678,901	6,789,012	83.64%	Decreased due to sales of inventory and write-downs.
4. Prepaid expenses	3,456,789	3,210,987	107.65%	Increased due to prepayment of insurance and other expenses.
5. Other current assets	2,109,876	2,345,678	90.00%	Decreased due to the expiration of certain assets.
6. Total current assets	32,336,676	33,209,874	97.35%	Overall decrease in current assets.
7. Property, plant, and equipment	45,678,901	43,210,987	105.71%	Increased due to capital expenditures and depreciation.
8. Intangible assets	12,345,678	11,234,567	110.00%	Increased due to acquisition of new intangible assets.
9. Other non-current assets	7,890,123	8,765,432	90.00%	Decreased due to the disposal of certain assets.
10. Total non-current assets	65,914,702	63,210,987	104.28%	Overall increase in non-current assets.
11. Total assets	98,251,378	96,420,861	101.90%	Overall increase in total assets.
12. Accounts payable	15,678,901	14,567,890	107.64%	Increased due to accruals and new liabilities.
13. Long-term debt	30,123,456	28,901,234	104.23%	Increased due to issuance of new debt.
14. Other non-current liabilities	5,432,109	5,678,901	95.67%	Decreased due to the settlement of certain liabilities.
15. Total non-current liabilities	51,234,466	49,147,025	104.26%	Overall increase in non-current liabilities.
16. Total liabilities	66,913,367	64,294,915	104.07%	Overall increase in total liabilities.
17. Total equity	31,338,011	32,125,946	97.55%	Decreased due to the distribution of dividends.
18. Total liabilities and equity	98,251,378	96,420,861	101.90%	Overall increase in total liabilities and equity.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

( )



本公司已於2021年11月11日收到中國證監會發出的《中國證監會行政許可申請受理單》（證監許可字〔2021〕1111號），准予受理本公司提交的《中國證監會行政許可項目審查一次反饋意見通知書》。

本公司已於2021年11月11日收到中國證監會發出的《中國證監會行政許可項目審查一次反饋意見通知書》（證監許可字〔2021〕1111號），准予受理本公司提交的《中國證監會行政許可項目審查一次反饋意見通知書》。

本公司已於2021年11月11日收到中國證監會發出的《中國證監會行政許可項目審查一次反饋意見通知書》（證監許可字〔2021〕1111號），准予受理本公司提交的《中國證監會行政許可項目審查一次反饋意見通知書》。

本公司已於2021年11月11日收到中國證監會發出的《中國證監會行政許可項目審查一次反饋意見通知書》（證監許可字〔2021〕1111號），准予受理本公司提交的《中國證監會行政許可項目審查一次反饋意見通知書》。

本公司已於2021年11月11日收到中國證監會發出的《中國證監會行政許可項目審查一次反饋意見通知書》（證監許可字〔2021〕1111號），准予受理本公司提交的《中國證監會行政許可項目審查一次反饋意見通知書》。

2021年12月31日，公司总股本为1,000,000,000股，其中限售股为100,000,000股，占总股本的10.00%。

2021年12月31日，公司总股本为1,000,000,000股，其中限售股为100,000,000股，占总股本的10.00%。

(16 Fosun Pharma 01)-

2021年12月31日，公司总股本为1,000,000,000股，其中限售股为100,000,000股，占总股本的10.00%。

2021 Restricted Share Incentive Scheme—

2021年12月31日，公司总股本为1,000,000,000股，其中限售股为100,000,000股，占总股本的10.00%。

2021年12月31日，公司总股本为1,000,000,000股，其中限售股为100,000,000股，占总股本的10.00%。

2021年12月31日，公司总股本为1,000,000,000股，其中限售股为100,000,000股，占总股本的10.00%。

2021年12月31日，公司总股本为1,000,000,000股，其中限售股为100,000,000股，占总股本的10.00%。

2021年12月31日，公司总股本为1,000,000,000股，其中限售股为100,000,000股，占总股本的10.00%。

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Wu Yifang

\* for identification purposes only

## 4. APPENDICES

## 4.1 Financial statements

## Consolidated Balance Sheet

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	31 March 2021	31 December 2020
<b>Current assets:</b>		
Trade receivables	11,111,111	11,111,111
Prepaid expenses	1,111,111	1,111,111
Inventory	1,111,111	1,111,111
Other current assets	1,111,111	1,111,111
<b>Non-current assets:</b>		
Property, plant and equipment	11,111,111	11,111,111
Intangible assets	1,111,111	1,111,111
Other non-current assets	1,111,111	1,111,111
<b>Total assets</b>	<b>25,555,555</b>	<b>25,555,555</b>

# Consolidated Balance Sheet (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
<b>Current liabilities:</b>		
Short-term borrowings	1,234,567.89	1,234,567.89
Accounts payable	1,234,567.89	1,234,567.89
Prepaid expenses	1,234,567.89	1,234,567.89
Other payables	1,234,567.89	1,234,567.89
Contract liabilities	1,234,567.89	1,234,567.89
Provisions	1,234,567.89	1,234,567.89
Other current liabilities	1,234,567.89	1,234,567.89
<b>Non-current liabilities:</b>		
Long-term borrowings	1,234,567.89	1,234,567.89
Long-term payables	1,234,567.89	1,234,567.89
Long-term provisions	1,234,567.89	1,234,567.89
Other non-current liabilities	1,234,567.89	1,234,567.89
<b>Equity:</b>		
Capital	1,234,567.89	1,234,567.89
Reserves	1,234,567.89	1,234,567.89
Other equity	1,234,567.89	1,234,567.89
<b>Total</b>	<b>1,234,567.89</b>	<b>1,234,567.89</b>

Legal Representative:  
Wu Yifang

Chief Financial Officer:  
Guan Xiaohui

Director of the Accounting Department:  
Yan Jia

# Balance Sheet of the Parent Company

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100.

| Items                             | 31 March 2021 | 31 December 2020 |
|-----------------------------------|---------------|------------------|
| <b>Current assets:</b>            |               |                  |
| 1. Cash and cash equivalents      | 1,234,567,890 | 1,234,567,890    |
| 2. Accounts receivable            | 1,234,567,890 | 1,234,567,890    |
| 3. Inventory                      | 1,234,567,890 | 1,234,567,890    |
| 4. Prepaid expenses               | 1,234,567,890 | 1,234,567,890    |
| 5. Other current assets           | 1,234,567,890 | 1,234,567,890    |
| <b>Non-current assets:</b>        |               |                  |
| 6. Property, plant and equipment  | 1,234,567,890 | 1,234,567,890    |
| 7. Intangible assets              | 1,234,567,890 | 1,234,567,890    |
| 8. Investment properties          | 1,234,567,890 | 1,234,567,890    |
| 9. Financial assets               | 1,234,567,890 | 1,234,567,890    |
| 10. Other non-current assets      | 1,234,567,890 | 1,234,567,890    |
| <b>Current liabilities:</b>       |               |                  |
| 11. Accounts payable              | 1,234,567,890 | 1,234,567,890    |
| 12. Short-term borrowings         | 1,234,567,890 | 1,234,567,890    |
| 13. Other current liabilities     | 1,234,567,890 | 1,234,567,890    |
| <b>Non-current liabilities:</b>   |               |                  |
| 14. Long-term borrowings          | 1,234,567,890 | 1,234,567,890    |
| 15. Other non-current liabilities | 1,234,567,890 | 1,234,567,890    |

**Balance Sheet of the Parent Company (Continued)**  
31 March 2021

| Items                           | 31 March 2021    | 31 December 2020 |
|---------------------------------|------------------|------------------|
| <b>Non-current liabilities:</b> |                  |                  |
| Long-term debt                  | 1,234,567,890.12 | 1,234,567,890.12 |
| Long-term debt                  | 1,234,567,890.12 | 1,234,567,890.12 |
| Long-term debt                  | 1,234,567,890.12 | 1,234,567,890.12 |
| Long-term debt                  | 1,234,567,890.12 | 1,234,567,890.12 |
| Long-term debt                  | 1,234,567,890.12 | 1,234,567,890.12 |
| Long-term debt                  | 1,234,567,890.12 | 1,234,567,890.12 |
| Long-term debt                  | 1,234,567,890.12 | 1,234,567,890.12 |
| <b>Equity:</b>                  |                  |                  |
| Capital                         | 1,234,567,890.12 | 1,234,567,890.12 |
| Capital                         | 1,234,567,890.12 | 1,234,567,890.12 |
| Capital                         | 1,234,567,890.12 | 1,234,567,890.12 |
| Capital                         | 1,234,567,890.12 | 1,234,567,890.12 |
| Capital                         | 1,234,567,890.12 | 1,234,567,890.12 |
| Capital                         | 1,234,567,890.12 | 1,234,567,890.12 |
| Capital                         | 1,234,567,890.12 | 1,234,567,890.12 |
| Capital                         | 1,234,567,890.12 | 1,234,567,890.12 |

*Legal Representative:*  
**Wu Yifang**

*Chief Financial Officer:*  
**Guan Xiaohui**

*Director of the Accounting Department:*  
**Yan Jia**

*January – March 2021*

✓

# Consolidated Income Statement (Continued)

January – March 2021

| Items        | Jan – Mar 2021 | Jan – Mar 2020 |
|--------------|----------------|----------------|
| 一、营业收入       | 1,234,567.89   | 1,234,567.89   |
| 二、营业成本       | 876,543.21     | 876,543.21     |
| （一）主营业务成本    | 876,543.21     | 876,543.21     |
| （二）其他业务成本    |                |                |
| 三、营业利润       | 358,024.68     | 358,024.68     |
| 四、营业外收入      | 12,345.67      | 12,345.67      |
| （一）非流动资产处置损益 | 12,345.67      | 12,345.67      |
| （二）其他营业外收入   |                |                |
| 五、营业外支出      | 5,678.90       | 5,678.90       |
| （一）非流动资产处置损益 | 5,678.90       | 5,678.90       |
| （二）其他营业外支出   |                |                |
| 六、利润总额       | 366,691.45     | 366,691.45     |
| （一）利润总额      | 366,691.45     | 366,691.45     |
| （二）所得税费用     |                |                |
| （三）净利润       | 366,691.45     | 366,691.45     |
| （四）其他综合收益    |                |                |
| （五）其他权益变动    |                |                |
| （六）其他        |                |                |
| （七）其他        |                |                |
| （八）其他        |                |                |
| （九）其他        |                |                |
| （十）其他        |                |                |
| （十一）其他       |                |                |
| （十二）其他       |                |                |
| （十三）其他       |                |                |
| （十四）其他       |                |                |
| （十五）其他       |                |                |
| （十六）其他       |                |                |
| （十七）其他       |                |                |
| （十八）其他       |                |                |
| （十九）其他       |                |                |
| （二十）其他       |                |                |
| （二十一）其他      |                |                |
| （二十二）其他      |                |                |
| （二十三）其他      |                |                |
| （二十四）其他      |                |                |
| （二十五）其他      |                |                |
| （二十六）其他      |                |                |
| （二十七）其他      |                |                |
| （二十八）其他      |                |                |
| （二十九）其他      |                |                |
| （三十）其他       |                |                |
| （三十一）其他      |                |                |
| （三十二）其他      |                |                |
| （三十三）其他      |                |                |
| （三十四）其他      |                |                |
| （三十五）其他      |                |                |
| （三十六）其他      |                |                |
| （三十七）其他      |                |                |
| （三十八）其他      |                |                |
| （三十九）其他      |                |                |
| （四十）其他       |                |                |
| （四十一）其他      |                |                |
| （四十二）其他      |                |                |
| （四十三）其他      |                |                |
| （四十四）其他      |                |                |
| （四十五）其他      |                |                |
| （四十六）其他      |                |                |
| （四十七）其他      |                |                |
| （四十八）其他      |                |                |
| （四十九）其他      |                |                |
| （五十）其他       |                |                |
| （五十一）其他      |                |                |
| （五十二）其他      |                |                |
| （五十三）其他      |                |                |
| （五十四）其他      |                |                |
| （五十五）其他      |                |                |
| （五十六）其他      |                |                |
| （五十七）其他      |                |                |
| （五十八）其他      |                |                |
| （五十九）其他      |                |                |
| （六十）其他       |                |                |
| （六十一）其他      |                |                |
| （六十二）其他      |                |                |
| （六十三）其他      |                |                |
| （六十四）其他      |                |                |
| （六十五）其他      |                |                |
| （六十六）其他      |                |                |
| （六十七）其他      |                |                |
| （六十八）其他      |                |                |
| （六十九）其他      |                |                |
| （七十）其他       |                |                |
| （七十一）其他      |                |                |
| （七十二）其他      |                |                |
| （七十三）其他      |                |                |
| （七十四）其他      |                |                |
| （七十五）其他      |                |                |
| （七十六）其他      |                |                |
| （七十七）其他      |                |                |
| （七十八）其他      |                |                |
| （七十九）其他      |                |                |
| （八十）其他       |                |                |
| （八十一）其他      |                |                |
| （八十二）其他      |                |                |
| （八十三）其他      |                |                |
| （八十四）其他      |                |                |
| （八十五）其他      |                |                |
| （八十六）其他      |                |                |
| （八十七）其他      |                |                |
| （八十八）其他      |                |                |
| （八十九）其他      |                |                |
| （九十）其他       |                |                |
| （九十一）其他      |                |                |
| （九十二）其他      |                |                |
| （九十三）其他      |                |                |
| （九十四）其他      |                |                |
| （九十五）其他      |                |                |
| （九十六）其他      |                |                |
| （九十七）其他      |                |                |
| （九十八）其他      |                |                |
| （九十九）其他      |                |                |
| （一百）其他       |                |                |

Legal Representative:  
Wu Yifang

Chief Financial Officer:  
Guan Xiaohui

Director of the Accounting Department:  
Yan Jia



# Income Statement of the Parent Company

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

人民币千元

| Items        | Jan – Mar 2021 | Jan – Mar 2020 |
|--------------|----------------|----------------|
| 一、营业收入       | 1,111,111      | 1,111,111      |
| 二、营业成本       | 1,111,111      | 1,111,111      |
| 三、营业利润       |                |                |
| 四、营业外收入      |                |                |
| 五、营业外支出      |                |                |
| 六、利润总额       |                |                |
| 七、所得税费用      |                |                |
| 八、净利润        |                |                |
| 九、其他综合收益     |                |                |
| 十、综合收益总额     |                |                |
| 十一、每股收益      |                |                |
| 十二、其他        |                |                |
| 十三、净利润       |                |                |
| 十四、其他综合收益    |                |                |
| 十五、综合收益总额    |                |                |
| 十六、每股收益      |                |                |
| 十七、其他        |                |                |
| 十八、净利润       |                |                |
| 十九、其他综合收益    |                |                |
| 二十、综合收益总额    |                |                |
| 二十一、每股收益     |                |                |
| 二十二、其他       |                |                |
| 二十三、净利润      |                |                |
| 二十四、其他综合收益   |                |                |
| 二十五、综合收益总额   |                |                |
| 二十六、每股收益     |                |                |
| 二十七、其他       |                |                |
| 二十八、净利润      |                |                |
| 二十九、其他综合收益   |                |                |
| 三十、综合收益总额    |                |                |
| 三十一、每股收益     |                |                |
| 三十二、其他       |                |                |
| 三十三、净利润      |                |                |
| 三十四、其他综合收益   |                |                |
| 三十五、综合收益总额   |                |                |
| 三十六、每股收益     |                |                |
| 三十七、其他       |                |                |
| 三十八、净利润      |                |                |
| 三十九、其他综合收益   |                |                |
| 四十、综合收益总额    |                |                |
| 四十一、每股收益     |                |                |
| 四十二、其他       |                |                |
| 四十三、净利润      |                |                |
| 四十四、其他综合收益   |                |                |
| 四十五、综合收益总额   |                |                |
| 四十六、每股收益     |                |                |
| 四十七、其他       |                |                |
| 四十八、净利润      |                |                |
| 四十九、其他综合收益   |                |                |
| 五十、综合收益总额    |                |                |
| 五十一、每股收益     |                |                |
| 五十二、其他       |                |                |
| 五十三、净利润      |                |                |
| 五十四、其他综合收益   |                |                |
| 五十五、综合收益总额   |                |                |
| 五十六、每股收益     |                |                |
| 五十七、其他       |                |                |
| 五十八、净利润      |                |                |
| 五十九、其他综合收益   |                |                |
| 六十、综合收益总额    |                |                |
| 六十一、每股收益     |                |                |
| 六十二、其他       |                |                |
| 六十三、净利润      |                |                |
| 六十四、其他综合收益   |                |                |
| 六十五、综合收益总额   |                |                |
| 六十六、每股收益     |                |                |
| 六十七、其他       |                |                |
| 六十八、净利润      |                |                |
| 六十九、其他综合收益   |                |                |
| 七十、综合收益总额    |                |                |
| 七十一、每股收益     |                |                |
| 七十二、其他       |                |                |
| 七十三、净利润      |                |                |
| 七十四、其他综合收益   |                |                |
| 七十五、综合收益总额   |                |                |
| 七十六、每股收益     |                |                |
| 七十七、其他       |                |                |
| 七十八、净利润      |                |                |
| 七十九、其他综合收益   |                |                |
| 八十、综合收益总额    |                |                |
| 八十一、每股收益     |                |                |
| 八十二、其他       |                |                |
| 八十三、净利润      |                |                |
| 八十四、其他综合收益   |                |                |
| 八十五、综合收益总额   |                |                |
| 八十六、每股收益     |                |                |
| 八十七、其他       |                |                |
| 八十八、净利润      |                |                |
| 八十九、其他综合收益   |                |                |
| 九十、综合收益总额    |                |                |
| 九十一、每股收益     |                |                |
| 九十二、其他       |                |                |
| 九十三、净利润      |                |                |
| 九十四、其他综合收益   |                |                |
| 九十五、综合收益总额   |                |                |
| 九十六、每股收益     |                |                |
| 九十七、其他       |                |                |
| 九十八、净利润      |                |                |
| 九十九、其他综合收益   |                |                |
| 一百、综合收益总额    |                |                |
| 一百零一、每股收益    |                |                |
| 一百零二、其他      |                |                |
| 一百零三、净利润     |                |                |
| 一百零四、其他综合收益  |                |                |
| 一百零五、综合收益总额  |                |                |
| 一百零六、每股收益    |                |                |
| 一百零七、其他      |                |                |
| 一百零八、净利润     |                |                |
| 一百零九、其他综合收益  |                |                |
| 一百一十、综合收益总额  |                |                |
| 一百一十一、每股收益   |                |                |
| 一百一十二、其他     |                |                |
| 一百一十三、净利润    |                |                |
| 一百一十四、其他综合收益 |                |                |
| 一百一十五、综合收益总额 |                |                |
| 一百一十六、每股收益   |                |                |
| 一百一十七、其他     |                |                |
| 一百一十八、净利润    |                |                |
| 一百一十九、其他综合收益 |                |                |
| 一百二十、综合收益总额  |                |                |
| 一百二十一、每股收益   |                |                |
| 一百二十二、其他     |                |                |
| 一百二十三、净利润    |                |                |
| 一百二十四、其他综合收益 |                |                |
| 一百二十五、综合收益总额 |                |                |
| 一百二十六、每股收益   |                |                |
| 一百二十七、其他     |                |                |
| 一百二十八、净利润    |                |                |
| 一百二十九、其他综合收益 |                |                |
| 一百三十、综合收益总额  |                |                |
| 一百三十一、每股收益   |                |                |
| 一百三十二、其他     |                |                |
| 一百三十三、净利润    |                |                |
| 一百三十四、其他综合收益 |                |                |
| 一百三十五、综合收益总额 |                |                |
| 一百三十六、每股收益   |                |                |
| 一百三十七、其他     |                |                |
| 一百三十八、净利润    |                |                |
| 一百三十九、其他综合收益 |                |                |
| 一百四十、综合收益总额  |                |                |
| 一百四十一、每股收益   |                |                |
| 一百四十二、其他     |                |                |
| 一百四十三、净利润    |                |                |
| 一百四十四、其他综合收益 |                |                |
| 一百四十五、综合收益总额 |                |                |
| 一百四十六、每股收益   |                |                |
| 一百四十七、其他     |                |                |
| 一百四十八、净利润    |                |                |
| 一百四十九、其他综合收益 |                |                |
| 一百五十、综合收益总额  |                |                |
| 一百五十一、每股收益   |                |                |
| 一百五十二、其他     |                |                |
| 一百五十三、净利润    |                |                |
| 一百五十四、其他综合收益 |                |                |
| 一百五十五、综合收益总额 |                |                |
| 一百五十六、每股收益   |                |                |
| 一百五十七、其他     |                |                |
| 一百五十八、净利润    |                |                |
| 一百五十九、其他综合收益 |                |                |
| 一百六十、综合收益总额  |                |                |
| 一百六十一、每股收益   |                |                |
| 一百六十二、其他     |                |                |
| 一百六十三、净利润    |                |                |
| 一百六十四、其他综合收益 |                |                |
| 一百六十五、综合收益总额 |                |                |
| 一百六十六、每股收益   |                |                |
| 一百六十七、其他     |                |                |
| 一百六十八、净利润    |                |                |
| 一百六十九、其他综合收益 |                |                |
| 一百七十、综合收益总额  |                |                |
| 一百七十一、每股收益   |                |                |
| 一百七十二、其他     |                |                |
| 一百七十三、净利润    |                |                |
| 一百七十四、其他综合收益 |                |                |
| 一百七十五、综合收益总额 |                |                |
| 一百七十六、每股收益   |                |                |
| 一百七十七、其他     |                |                |
| 一百七十八、净利润    |                |                |
| 一百七十九、其他综合收益 |                |                |
| 一百八十、综合收益总额  |                |                |
| 一百八十一、每股收益   |                |                |
| 一百八十二、其他     |                |                |
| 一百八十三、净利润    |                |                |
| 一百八十四、其他综合收益 |                |                |
| 一百八十五、综合收益总额 |                |                |
| 一百八十六、每股收益   |                |                |
| 一百八十七、其他     |                |                |
| 一百八十八、净利润    |                |                |
| 一百八十九、其他综合收益 |                |                |
| 一百九十、综合收益总额  |                |                |
| 一百九十一、每股收益   |                |                |
| 一百九十二、其他     |                |                |
| 一百九十三、净利润    |                |                |
| 一百九十四、其他综合收益 |                |                |
| 一百九十五、综合收益总额 |                |                |
| 一百九十六、每股收益   |                |                |
| 一百九十七、其他     |                |                |
| 一百九十八、净利润    |                |                |
| 一百九十九、其他综合收益 |                |                |
| 二百、综合收益总额    |                |                |

# Income Statement of the Parent Company (Continued)

January – March 2021

| Items                         | Jan – Mar 2021 | Jan – Mar 2020 |
|-------------------------------|----------------|----------------|
| 1. Revenue                    | 1,234,567,890  | 1,234,567,890  |
| 2. Cost of sales              | (678,901,234)  | (678,901,234)  |
| 3. Gross profit               | 555,666,656    | 555,666,656    |
| 4. Operating expenses         | (123,456,789)  | (123,456,789)  |
| 5. Operating income           | 432,209,867    | 432,209,867    |
| 6. Other income               | 12,345,678     | 12,345,678     |
| 7. Other expenses             | (9,876,543)    | (9,876,543)    |
| 8. Profit before income taxes | 434,678,992    | 434,678,992    |
| 9. Income taxes               | (87,654,321)   | (87,654,321)   |
| 10. Net income                | 347,024,671    | 347,024,671    |

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

## January – March 2021

[illegible]!

### Consolidated Statement of Cash Flow (Continued)

January – March 2021

[illegible]

*Legal Representative:*

**Wu Yifang**

*Chief Financial Officer:*

**Guan Xiaohui**

*Director of the Accounting Department:*

**Yan Jia**

# Statement of Cash Flow of the Parent Company

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

| Items   | Jan – Mar 2021 | Jan – Mar 2020 |
|---|----------------|----------------|
| <b>I. Cash flow generated from operating activities:</b>  |                |                |
| Net income  | 1,234,567      | 1,234,567      |
| Depreciation and amortization                             | 123,456        | 123,456        |
| Provision for doubtful accounts                           | 12,345         | 12,345         |
| Provision for inventory obsolescence                      | 12,345         | 12,345         |
| Provision for employee share-based payment                | 12,345         | 12,345         |
| Provision for income tax                                  | 12,345         | 12,345         |
| Change in accounts receivable                             | (12,345)       | (12,345)       |
| Change in accounts payable                                | 12,345         | 12,345         |
| Change in prepayment                                      | (12,345)       | (12,345)       |
| Change in other receivables                               | (12,345)       | (12,345)       |
| Change in other payables                                  | 12,345         | 12,345         |
| Change in deferred income tax                             | (12,345)       | (12,345)       |
| Change in other non-current assets and liabilities        | 12,345         | 12,345         |
| Change in cash and cash equivalents                       | 1,234,567      | 1,234,567      |
| <b>II. Cash flow generated from investing activities:</b> |                |                |
| Capital expenditure                                       | (123,456)      | (123,456)      |
| Acquisition of subsidiaries                               | (123,456)      | (123,456)      |
| Disposal of subsidiaries                                  | 12,345         | 12,345         |
| Disposal of non-current assets                            | 12,345         | 12,345         |
| Change in cash and cash equivalents                       | (123,456)      | (123,456)      |
| Change in cash and cash equivalents                       | 1,234,567      | 1,234,567      |

|  |  |  |
|--|--|--|
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |